New drug: Lurbinectedin for small cell lung cancer

LurbinectedinApproved indication: small cell lung cancer Zepzelca (Specialised Therapeutics) vials containing 4 mg powder for reconstitution Metastatic small cell lung cancer has a poor prognosis.Although many patients will have a response to chemotherapy, the cancer soon relapses.Their median survival can then be less than a year, so there is a need for effective second-line treatments.Lurbinectedin is a cytotoxic drug with some similarity to trabectedin.It binds to DNA, affecting DNA repair and transcription leading to cell death.